Preparing for success in modernizing the science behind the development and regulation of medical products
The Course
The syllabus of the ACDRS Course covers all aspects of global pharmaceutical medicine and medical product development sciences. This includes the discovery and development of new therapeutics, biopharmaceutical sciences, clinical pharmacology, pharmacometrics, learning-trial methodology, good clinical practice and ethics, pharmacovigilance and risk management, biostatistics, exploratory/confirmatory trial design, regulatory affairs, optimization, health economics, project and portfolio management, marketing, and new therapeutic approaches. Participants will be involved in lectures, panel discussions, team-oriented case studies, and interactive learning.
The ACDRS Course consists of six sessions over a period of approximately eleven months, including “team” involvement in mentored, case-oriented breakout discussions. Each session is three days of eight hours each in Washington, DC. In addition, approximately eight hours of preparation per session is required to prepare for the case studies and intersession activities.
What Will You Gain from Attending this Course?
At the end of these six sessions, the course participant should be able to understand how to incorporate the latest innovative biopharmaceutical development strategies, methodologies, and tools to:
Explain the entire medical product lifecycle, from molecule or device concept to marketplace
Apply optimization principles and latest cutting-edge science for improving R&D productivity and increasing success rates
Analyze a development organization’s structure to understand the integration and contribution of different functional areas to each stage of product development and post-marketing
Prepare for future developments and changes in the global pharmaceutical, health economics and business environments, as it impacts discovery, development, lifecycle management, regulatory, and business evaluations for medical products
Design, evaluate, and manage integrated global product development programs for pharmaceutical, biologic, devices, and other innovative products
Analyze and evaluate the R&D portfolio
Devise timely Go/No Go decision-making criteria derived from the target product profile, procedures based upon critical analyses of non-clinical and clinical data sets, and literature and competitor information, leading to improved success rates for new drug candidates and devices
Incorporate present and future regulatory policies, guidances, and opportunities into strategies spanning all stages of discovery, development, and registration
Participate in decision-making discussions with comprehensive knowledge of medical product development from discovery to market
Address real world challenges encountered during the development, manufacturing, review, and commercialization of United States Food and Drug Administration (US FDA) and globally regulated medical products
Incorporate commercial valuations and investment return estimates into milestone decisions, including early in development
Explain the legal basis of regulations, patents, and recent and new changes in the law, policies, and governmental initiatives affecting drug development and regulatory sciences
Apply cross-functional product development knowledge to prepare for their next career step
Session 1
The Medical Product Development Enterprise: Past, Present, and Future Perspectives
Session Co-chairpersons: Charlie T. Gombar, PhD, ACDRS Director and Daniela Drago, PhD RAC FRAPS FTOPRA, Expert Consultant, NDA Partners
Learning Outcomes
At the end of Session 1, the course participant should be able to:
Summarize the history of the pharmaceutical enterprise
Discuss the principles and organization of global pharmaceutical research and label-driven product development
Discuss the future directions of global pharmaceutical, health economics and business environments, and their implications for drug selection, drug development, regulatory and business evaluations
Identify innovation in discovery and development as a response to patient, medical and market needs
Develop a Target Product Profile to set the strategy for medical product discovery and development programs and projects
Explain US Food and Drug Administration regulatory pathways for drugs, biologics, biosimilars, cellular and gene therapies and combination products
Topics
History of the pharmaceutical enterprise
Development timelines
Principles of contemporary drug development and regulatory science
Patient perspectives in medical product development
Pharmacoeconomics, health technology assessment, and methods for comparison of economic value for different products
Global health trends, disease management, and their effect on health outcomes
Regulatory pathways for drugs and biologics
Regulatory landscape and development challenges in pediatric, cell and gene therapies, and novel treatment modalities
Special topics based on cutting edge science, changing regulations, controversies, etc.
Decision points in development of small and large molecules
Management science: Portfolio, projects, and teams
Target product profile: A key strategic tool in product development
Session 2
Learning Trials: From Discovery to First in Humans
Session Co-chairpersons: Paolo Vicini, PhD MBA, Chief Development Officer, Confo Therapeutics and Gary Skiles, PhD, Consultant
Learning Outcomes
At the end of Session 2, the course participant should be able to:
Describe the principles of drug discovery including in vitro and in vivo techniques used to identify and characterize the chemical, biological, and pharmacological properties of drug candidates
Explain the fundamentals of pharmacokinetics (PK) and describe the use of preclinical data to predict human PK
Identify the methodology for selecting, optimizing, formulating, assessing the safety, and protecting the intellectual property of small molecule and biologic preclinical drug candidates
Apply clinical pharmacology principles for the early assessment and development of clinical candidates
Describe how biomarkers are integrated into and used to accelerate the drug development process
Discuss the principles of and regulations for conducting nonclinical and first-in-human clinical studies
Topics
PK, pharmacodynamics (PD) and absorption, distribution, metabolism, and excretion (ADME)
Discovery chemistry
Discovery of biologics
Chemistry, manufacturing, and control (CMC)
Selection criteria for therapeutic monoclonal antibodies
Strategies and approaches for preclinical to clinical translation
Intellectual property in drug discovery and development
Strategies for predicting human PK, exposure-response, and safety
Determinants of human PK variability
Guidelines and Beyond for nonclinical toxicology
Strategies for successful toxicology investigations
Devices to support early drug development
Session 3
Learning and Confirming Trials: Finding and Confirming the Right Dose
Session Co-chairpersons: Diane K. Jorkasky, MD FACP, Consultant to Pharma and Michael J. Fossler, PharmD PhD FCP, Executive Consultant/Vice-President, Strategic Consulting, Cytel
Learning Outcomes
At the end of Session 3, the course participant should be able to:
Discuss strategy for taking drugs into humans and through proof of concept in patients
Discuss the appropriate use of preclinical data for estimating safe and potentially effective dosing in early human clinical studies, especially the limitations of such predictions
Discuss the pros and cons of early trial designs, the safety management of subjects in these studies, and the decisions required on limited data
Discuss model-informed drug development (MIDD)
Address approaches to measuring change in disease, drug efficacy, and safety as generally modulated by dose-exposure-response
Discuss and plan strategies for determining dose-response prospectively and finding individual dose-exposure-response by exploratory analysis
Explain the various aspects of the conduct of a clinical trial
Topics
Choosing doses/exposures for first in human studies, and the role of pharmacokinetics-pharmacodynamics (PKPD) modeling and simulation
Biomarker strategy and qualification for efficacy and safety
Developing drugs from first in human dosing to understanding dose-exposure-response in patients – efficacy and safety
Regulatory perspective: Utilizing pharmacodynamic biomarkers in drug development
Quantitative principles for drug development decision-making
Dose-exposure ranging in early drug development
Exposure response and drug-drug interaction
Optimization of clinical trial design
Conundrums of the learning phase of drug development
Proof of concept
Data utilization for decision making at the end of the learning phase
Session 4
Statistics: Design, Analysis, and Interpretation of Clinical Trials
Co-chairpersons: Freda Cooner, PhD, Senior Director, Biostatistics, Eli Lilly & Company and Telba Irony, PhD, Senior Scientific Director, The Janssen Pharmaceutical Companies of Johnson & Johnson
Learning Outcomes
At the end of Session 4, the course participant should be able to:
Evaluate clinical trial designs and statistical analysis plans to generate credible evidence about a treatment effect
Interpret clinical trial data to evaluate whether the data constitute substantial evidence of a treatment effect for a regulatory approved label
Understand the concepts underlying frequentist and Bayesian inference, including hypothesis testing, p-values and Bayesian posterior probabilities
Recognize the impact of multiple testing in clinical trials and methods to reduce false positive findings
Construct an appropriate estimand for a clinical trial using the ICH E9(R1) framework
Compare the pros and cons for various clinical trial designs, including adaptive designs and enrichment designs, and understand how modeling and simulation play an important role in trial optimization
Discuss considerations for sample size, power, false positive and false negative decisions emanating from interim analyses and final analyses of clinical trials
Apply statistical considerations for a confirmatory study design and design an analysis plan for a tailored subgroup for phase 3
Topics
Role of confirmatory phase in drug development
Statistical principles for clinical trials
Choice of control groups in clinical trials
Study objectives, hypothesis testing, sample size, and probability of study success
Multiplicity in clinical trials
Missing data and estimands
Interim analysis
Bayesian statistics
The design, analysis, and interpretation of a clinical endpoint trial
Modeling and simulation
Adaptive design in clinical trials and optimization
Design and analysis of adaptive clinical trials
Enrichment designs
Perspectives for developing a targeted medicine
Co-development of a diagnostic and targeted medicine
Statistical issues related to design, analysis, and reporting of gene therapy clinical trials
Multi-regional clinical trials
Safety assessment and surveillance
Pharmacovigilance
Session 5
Global Clinical Trial Authorization and Marketing Authorization Processes
Session Co-chairpersons: Daniela Drago, PhD RAC FRAPS FTOPRA, Expert Consultant, NDA Partners; and Christine E. Garnett, PharmD, Lead, Interdisciplinary Team for Cardiac Safety Studies and Clinical Analyst, United States Food and Drug Administration (US FDA)
Learning Outcomes
At the end of Session 5, the course participant should be able to:
Explain the requirements for various regulatory applications, including documentation and possible avenues for receiving advice from regulators
Discuss the procedures for regulatory oversight in the US, the European Union (EU), and China, including processes for starting a clinical trial and for marketing authorization in these jurisdictions
Discuss social corporate responsibility and its impact on low- and middle-income countries
Discuss special US regulatory procedures, regulatory strategies, and crisis management
Recall and apply the benefit-risk framework used by the US FDA for assessment of new drug applications
Topics
US FDA applicable laws, regulations, and guidance documents
FDA’s new drug clinical trial and marketing authorization review processes
US benefit-risk methodology and considerations
US labeling requirements
US regulatory actions and outcomes for NMEs, NDAs, and BLAs
US regulatory approaches to post-marketing
US regulatory requirements for rare diseases, pediatric therapeutics, and cell & gene therapies
Challenges with and approaches to multi-country clinical trials
US FDA advisory committee meetings and CHMP oral explanations
CMC section of regulatory applications
FDORA, PDUFA VII, and their impact on US FDA-regulated industry and US FDA
Starting a clinical trial and obtaining scientific advice in the EU, Japan, China, and the US
Procedures and approaches to obtain marketing authorizations from the European Medicines Agency (EMA), Pharmaceutical and Medical Devices Agency of Japan, National Medical Products Administration (NMPA) of China, and US FDA
Enhancing diversity in clinical trial populations
Real-world data and real-world evidence
Artificial intelligence and machine learning
Session 6
Integrated Product Development, Project Management, Portfolio Management, and Preparing for Transition to Market
Session Co-chairpersons: Charlie T. Gombar, PhD, ACDRS Director and Michael Dyszel, Vice President, Product Development Leader, Pyxis Oncology
Learning Outcomes
At the end of Session 6, the course participant should be able to:
Discuss the principles of project and portfolio management, including aspects of planning, project evaluation, and decision making
Explain the limitations of traditional portfolio management and propose innovative methods to improve portfolio management
Apply the principles of portfolio management to drive decision making in medical product development
Discuss the principles of business development, partnering, and alliance management throughout the lifecycle of a product
Apply the principles of regulatory requirements for advertising and promotion of a prescription drug
Practice leadership strategies for team interactions and other decision making
Topics
Portfolio management: principles, challenges, applications, and strategies
Role of licensing in portfolio management
Project management: principles, challenges, and strategies
Judgment under uncertainty
Integrated global strategy
Turning strategy into plans
Co-development and alliances
Strategic marketing (commercial) role in development
How to launch a new drug successfully into the market
Risk communication and prescription drug promotion
Promotional committee review simulation
Leadership strategies in drug development and regulation
"This has truly been the most useful and engaging training that I have ever attended. The content, presenters, and interaction with peers has been outstanding. The opportunity to learn from leaders in the industry is truly unique and provides a perspective that makes the ACDRS course so valuable. Whether you are new to product development, or have some experience in this field, you will undoubtedly find this informative and educational."
—Magda Michna, Chief Clinical, Regulatory and Medical Affairs Officer for STAAR Surgical